INTRODUCTION AND OBJECTIVES: Neuropilin 2 (NRP2) has been shown to be involved in prostate cancer (PCa) progression. It has already been demonstrated that NRP2 depletion results in accumulation of early endosome. This impairs the endocytic transport of EGFR leading to an arrest of functionally active EGFR and subsequently to aberrant ERK activation and cell death. Therefore, we investigated the association of NRP2 and EGFR expression with survival in PCa patients and the role of NRP2 depletion combined with EGFR inhibition in the PCa cell functioning.
METHODS: A tissue microarray was generated of prostatectomy tissue specimens from 400 PCa patients. The protein expression of NRP2 and EGFR was analyzed by immunohistochemistry. The prognostic impact of NRP2 and EGFR expression on overall (OS) and cancer-specific survival (CSS) was assessed. Additionally, in cisplatinsensitive and -resistant DU145 PCa cells, NRP2 was depleted by transfection of siRNA. The effects of EGFR-inhibition by Cetuximab combined with NRP2-depletion on down-stream targets of EGFR (ERK/ pERK Thr202/Tyr204 and AKT/pAKT Ser473 ) were analyzed by Western-Blot. Effects on apoptosis and migration were assessed by the Annexin V assay and Boyden chamber migration assay, respectively.
RESULTS: In patients with NRP2 expression, CSS was significantly shorter than in patients without NRP2 expression (15.5a vs. 16.1a, p¼0.007). EGFR expression alone was not associated with CSS. However, patients presenting with co-expression of EGFR and NRP2 showed a shorter CSS than patients with EGFR expression alone (13.4a vs. 16.3a, p¼0.01). The NRP2 expression emerged as an independent predictor for CSS (HR 2.36; 95%-CI 1.17-4.71; p¼0.016), but not EGFR-expression. Longlasting inhibition of ERK and AKT activation was shown especially in cisplatin-resistant DU145 cells after treatment with Cetuximab and NRP2-depletion. The combination of Cetuximab and NRP2-depletion led to an increased apoptosis and a decreased migration compared to Cetuximab alone, NRP2-depletion alone and without treatment in both cisplatin-sensitive and cisplatinresistant DU145 cells.
CONCLUSIONS: Co-expression of NRP2 and EGFR is associated with a significantly shorter CSS in patients with PCa. NRP2-depletion enhances the effects of EGFR-inhibition in DU145 PCa cells and may play a role as a new treatment combination especially in chemotherapy-resistant PCa.
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MP29-13 TUMOR ENDOTHELIAL CELLS AS A TARGETABLE GATEWAY THAT MODULATES ACCESS OF DRUGS TO CANCER CELLS
Yue Wu*, Michael Greene, Jianmin Wang, Gary Smith, Buffalo, NY INTRODUCTION AND OBJECTIVES: The human endothelial cell (EC) lining of the vasculature is preserved in primary xenografts of surgical remnants of human prostate cancer (CaP). Testosterone deprivation (T-D) induced apoptotic loss of 40-60% of ECs in CaP xenografts. This study investigated the consequences of targeted perturbation of the CaP EC compartment on access of chemotherapeutic agents to the CaP cells. Cisplatin (Pt), which targets slowly/non-proliferating cancer cells (CaP), was investigated because it is excluded by the membrane pumps/transporters of an intact EC barrier.
METHODS: nu/nu mice were castrated and implanted with a device for sustained delivery of T at human levels. Fresh human CaP or benign prostate tissue were transplanted and allowed to engraft for 30 days. The T delivery device was removed and mice were treated with Pt at different times after T-D. Xenografts were harvested, enzymatically disaggregated, and EC and CaP cells isolated using cell type-specific antibody-conjugated magnetic beads. Transcriptomes of EC and epithelial/CaP cells were obtained using RNASeq, and compared for cells recovered from fresh tissue, xenografts, and xenografts after T-D. Integrity of the EC barrier was evaluated using MRI; immunohistochemistry (IHC); and Photo-Acoustic Imaging. Pt-induced DNA adduct load was analyzed using Pt-adduct specific antibodies and Cytof.
RESULTS: The human EC barrier was disrupted transiently by T-D, and was restored by re-endothelialization, in spite of the absence of T. Transcriptomes of fresh tissue and xenografts validated that all cell types in xenografts were consistent with fresh tissue. Transcriptomes of EC and endothelial/CaP cells revealed a highly dynamic microenvironment in prostate tissue in response to T-D, including drug-related trans-membrane pumps/transporters. Increased CaP cell exposure to Pt was demonstrated by greater levels of Pt-DNA adducts in xenografts treated during the peak of EC apoptotic death induced by T-D.
CONCLUSIONS: Transient destruction of the EC barrier by T-D provides a therapeutically important "window" during which chemotherapeutic agents that are effectively excluded by an intact prostate EC e370 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Saturday, May 19, 2018 
